Among the most merciless of human diseases, glioblastoma has long defeated medicine not through brute resistance but through invisibility — tumor cells dispersing into healthy tissue beyond the reach of any blade or drug. Researchers from the University of Technology Sydney, Harvard, and Henan universities have now published work in Science Translational Medicine describing nanoparticles engineered to do two things at once: illuminate what surgeons cannot see, then destroy what they cannot safely remove. In mouse models, the approach produced complete survival where surgery alone could not, of
Dual-function nanoparticles show promise in glioblastoma surgery and treatment
Glioblastoma remains one of the most lethal brain cancers with only 7% five-year survival, affecting thousands of patients annually.
A single material that does two jobs in sequence
Mark
Why does glioblastoma recur so often, even after surgery?
Mimi
Because the tumor doesn't grow as a single mass. It spreads through the brain tissue like roots, so surgeons can't see all of it and can't safely remove all of it without damaging healthy brain. The cells left behind grow back.
Mark
And the blood-brain barrier—that's a real wall?
Mimi
Not literally, but functionally yes. It's a biological filter that keeps most drugs out of the brain. It's protective normally, but for cancer treatment it's a prison. Most therapies can't reach the tumor because they can't cross it.
Mark
So these nanoparticles solve both problems at once?
Mimi
They solve them sequentially. First, they help surgeons see more during the operation—tumor clusters as small as 44 micrometers light up under infrared light. Then, after surgery, the same particles become a treatment that destroys what the surgeon couldn't reach.
Mark
How does the same particle do two completely different things?
Mimi
The near-infrared light is the switch. During surgery, it activates fluorescence—the particle glows so surgeons can see. After surgery, the same light activates chemistry—platinum atoms in the particle convert the tumor's own hydrogen peroxide into oxygen, which weakens the cancer's defenses.
Mark
The mouse results—100 percent survival versus 42 days—that sounds almost too good.
Mimi
It is early. Mice are not people. The human brain is much larger, and we don't know yet if the particles will work at that scale or if they'll be safe in living patients. But it's the first real evidence the concept works at all.
Mark
What's the next step?
Mimi
Validation at human scale, then safety testing, then clinical trials. Years away. But if it holds up, surgeons could remove more tumor and treat more of what's left. For glioblastoma, that could change everything.
El Pulso
- Glioblastoma's 7% five-year survival rate is not a failure of effort but of tools — the tumor hides in brain tissue where neither scalpel nor drug can safely follow.
- The new nanoparticles use near-infrared light to make tumor clusters as small as 44 micrometers visible during surgery, surpassing the resolution of current clinical imaging.
- After surgery, the same material is reactivated with the same light to flood the remaining cancer cells with oxygen and heat, dismantling the low-oxygen environment tumors depend on to survive.
- In mouse trials, every animal treated with the dual approach survived to 60 days with no recurrence and no neurological damage — compared to an average 42-day survival with surgery alone.
- The distance between a promising mouse model and a human clinical trial is long and unguaranteed, but the platform addresses two of glioblastoma's most stubborn defenses in a single engineered tool.
Among the most merciless of human diseases, glioblastoma has long defeated medicine not through brute resistance but through invisibility — tumor cells dispersing into healthy tissue beyond the reach of any blade or drug. Researchers from the University of Technology Sydney, Harvard, and Henan universities have now published work in Science Translational Medicine describing nanoparticles engineered to do two things at once: illuminate what surgeons cannot see, then destroy what they cannot safely remove. In mouse models, the approach produced complete survival where surgery alone could not, offering a rare foothold against a cancer that has yielded almost none.
Glioblastoma kills with a particular cruelty — not only because it is the most aggressive form of brain cancer, but because its cells spread through surrounding brain tissue like roots through soil, making complete surgical removal nearly impossible. Surgeons face an impossible choice between cutting too deep and leaving too much behind, while the blood-brain barrier blocks most drugs from reaching the tumor at all. Only about seven in a hundred patients survive five years.
A research team spanning the University of Technology Sydney, Harvard, and Henan universities has engineered a response built around a single tool that works in two stages. Their nanoparticles — structures existing at the atomic level — perform two entirely different functions, both triggered by the same wavelength of near-infrared light. During surgery, a fluorescent dye on the material glows under that light, allowing surgeons to detect tumor clusters as small as 44 micrometers, a resolution beyond current clinical imaging. A targeting molecule also helps the particles cross the blood-brain barrier and accumulate specifically in glioma cells.
Once the visible tumor is removed, the same material is placed into the surgical cavity and reactivated. Platinum atoms embedded in the structure convert hydrogen peroxide — naturally present in tumor cells — into oxygen, stripping away the low-oxygen environment cancer depends on. Simultaneously, light-generated heat and reactive molecules destroy the microscopic cells hiding in tissue margins where surgery cannot safely reach.
In mouse models, every animal treated with the dual approach survived to 60 days with no tumor recurrence and no detectable neurological damage. Mice receiving surgery alone survived an average of 42 days. The researchers are careful to note that these are early animal results, and the path to human clinical trials remains long and uncertain. But for a disease where recurrence is the defining challenge, a tool that lets surgeons see more and treat more in the same procedure represents a meaningful step forward.
Glioblastoma kills with a particular cruelty. It is the most aggressive form of brain cancer, and the statistics that follow from that fact are grim: only about seven in every hundred people diagnosed with it survive five years. The disease is relentless partly because of its nature—tumor cells do not stay neatly in one place but spread through the surrounding brain tissue like roots through soil. A surgeon removing the visible mass faces an impossible choice: cut deeper and risk destroying healthy brain alongside the cancer, or leave behind cells that will almost certainly grow back. Even chemotherapy and radiation struggle to help, blocked by the blood-brain barrier, a biological wall that keeps most drugs from reaching the brain at all.
A team of researchers from the University of Technology Sydney, Harvard, and Henan universities has engineered a response to this problem that works in two stages with a single tool. They have built nanoparticles—structures so small they exist at the atomic level—that perform two completely different jobs, one after the other, both triggered by the same wavelength of near-infrared light. The work, published in Science Translational Medicine, represents what Dr. Bingyang Shi, a chair professor of nanomedicine at UTS, describes as a "double-punch" approach: a precise guide for the surgeon's hand during the operation, and then a targeted treatment for what the surgeon's hand could not reach.
The engineering is intricate. The platform is built around an ultrathin, two-dimensional sheet—imagine a surface just atoms thick—studded with individual atoms placed one at a time using techniques borrowed from semiconductor manufacturing. This atomic-scale precision gives the material its dual nature. During surgery, a fluorescent dye engineered onto the sheet glows under near-infrared light that is invisible to the human eye, allowing surgeons to see tumor cell clusters as small as 44 micrometers. That resolution exceeds what current clinical imaging tools can achieve. A targeting molecule attached to the material also helps it cross the blood-brain barrier and accumulate specifically in glioma cells, solving one of the disease's fundamental obstacles.
After the visible tumor is removed, the same material is placed into the surgical cavity and reactivated with the same light. Now it performs a different function. Platinum atoms embedded in the sheet convert hydrogen peroxide—a chemical naturally present in tumor cells—into oxygen. This matters because cancer cells thrive in low-oxygen environments; by flooding that space with oxygen, the treatment removes one of cancer's protective shields. Simultaneously, the light generates heat and reactive molecules that destroy the microscopic cancer cells that surgery could not reach, the ones hiding in the tissue margins where a surgeon's blade cannot safely go.
In mouse models of glioblastoma, the results were striking. Animals treated with this dual approach survived to 60 days with no tumor recurrence, a complete survival rate. Mice that received surgery alone survived an average of 42 days. The treated animals showed no detectable neurological or motor deficits in follow-up testing, suggesting the approach did not damage healthy brain function. These are early results, conducted in animals, not people. Dr. Shi is careful about this distinction. The imaging and therapeutic performance will need to be confirmed at the scale of a human brain, and the path from mouse models to human clinical trials is long and uncertain.
But if the approach continues to hold, the implications are significant. Surgeons could see more of the tumor during an operation and treat more of what remains afterward. For a disease where recurrence is one of the biggest challenges patients face, that represents a meaningful step forward. The work is still in its infancy, but it points toward a future where the tools we use to fight glioblastoma might be smarter, more precise, and more complete than they are today.
Citas Notables
We've engineered a single material that does two jobs in sequence. It's a precise guide for the surgeon during the operation, and then a targeted clean-up treatment afterwards.— Dr. Bingyang Shi, Chair Professor of Nanomedicine, University of Technology Sydney
The results are very encouraging, but this is still early-stage research carried out in mouse models, not in people—and that distinction is important.— Dr. Bingyang Shi
Quieres la nota completa?
Lee el original en News-Medical ↗
Health & Medicine